Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder
|ClinicalTrials.gov Identifier: NCT00293839|
Recruitment Status : Completed
First Posted : February 20, 2006
Last Update Posted : December 9, 2010
|Condition or disease||Intervention/treatment||Phase|
|Urinary Incontinence||Drug: oxybutynin chloride||Phase 3|
The objective of this study is to compare the efficacy and tolerability of DITROPAN® XL 10 mg once-daily and DETROL® LA 4 mg once-daily in the reduction of urge urinary incontinence episodes in female patients with overactive bladder. This is a multicenter, randomized, double-blind, parallel-group study with two active treatments. Screened patients are qualified for the study based on information obtained from seven consecutive 24-hour urinary diaries completed during the Baseline Week, and other eligibility criteria. Qualifying patients receive 12 weeks of treatment with DITROPAN® XL or DETROL® LA, with clinical visits at the end of Weeks 2, 4, 8, and 12.
Safety evaluations during the study include the collection of adverse events, laboratory tests including blood chemistry and urinalysis, physical examinations, vital signs (blood pressure and heart rate) and post-void residual urine volume. Over-encapsulated DITROPAN® XL, 10 mg tablets once-daily by mouth or over-encapsulated DETROL® LA, 4 mg capsules once daily by mouth. The treatment phase of the study runs for 12 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||790 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Comparison of the Efficacy and Tolerability of DITROPAN XL and DETROL LA in the Treatment of Overactive Bladder|
|Study Completion Date :||December 2002|
- The number of weekly urge urinary incontinence (Urge-UI) episodes at week 12, adjusted for the baseline value
- The number of total urinary incontinence (Total-UI) episodes at week 12; Void frequency at week 12; Urge-UI ,Total-UI, and Void frequence at weeks 2, 4, and 8; tolerability of the treatments during the 12-week treatment phase.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00293839
|Study Director:||Alza Corporation Clinical Trial||ALZA|